Skip to main content
. Author manuscript; available in PMC: 2023 Jun 9.
Published in final edited form as: Nature. 2022 May 25;606(7916):992–998. doi: 10.1038/s41586-022-04772-4

Extended Data Fig. 3 ∣. Protection from metastatic disease by vaccination following surgical removal of primary tumors.

Extended Data Fig. 3 ∣

a, c, Images of lung metastases from five representative mice per group immunized with Ctrl-vax (top two rows) or MICB-vax (bottom two rows). Mice were immunized following surgical removal of primary B16-BL6 (MICB) (n = 10 mice/group) (a) and 4T1 (MICB) (c) tumors (n = 13 mice/group), as described in Fig. 1f, g. b, d, Representative bright field images of H&E stained histological sections of lung metastases from mice with B16-BL6 (MICB) (b) or 4T1 (MICB) (d) tumors. e–f, Quantification of the number of metastases per H&E stained section (left) and percentage of area of lung section occupied by metastases (right) for mice immunized with Ctrl-vax (blue) or MICB-vax (red) following surgical removal of primary B16-BL6 (MICB) tumors (e) or 4T1 (MICB) tumors (f). Representative data from two experiments (a-f). Representative images of 5 histological lung sections per mouse (b, d), Two-tailed Mann Whitney test (e, f). Data depict mean+/− SEM.